How to beat rising inflation
A look back at the 1970s reveals what you should invest in if you’re not convinced inflation is “transitory”


The official narrative among the world’s central bankers is that inflation is “transitory”. Prices are rising now, but that’s just because we’re reopening the economy and supply chains are readjusting. In the longer run, we don’t need to worry. Perhaps.
But before you take the official view at face value, it’s worth remembering that almost no one in the mainstream economic establishment or in a position of monetary authority saw any of this coming at all. Soaring energy costs and rising wages in key parts of the labour market might wash out over the coming months, but if you’d rather be safe than sorry, how can you position yourself in case the official line is wrong (again)?
Investing to beat inflation
James Montier and Philip Pilkington have looked at how to position portfolios for inflation in a new paper for US asset manager GMO. They note that there are two aspects here – one is hedging against inflation in the short term, which is more applicable to institutional investors and traders. For long-term investors (such as MoneyWeek readers), the key is to find assets that operate as decent stores of value – they won’t necessarily react to every inflation move and might even struggle at points in the cycle, but over time they’ll deliver real returns.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The asset class most people turn to first is commodities. Yet as Montier and Pilkington note, one of the main reasons that commodities are seen as a great inflation hedge is because one in particular – oil – did tremendously well during the inflation of the 1970s (although to be fair, commodities in general “just about acted as a store of value”). The risk today is that oil shocks were a key component of the 1970s inflation and while that may be repeated there’s no guarantee.
Gold also did well over the decade, but the pair are cautious on its prospects – due to its lack of cash flows, “we really don’t have a way of knowing whether we are paying a high or a low price for any insurance properties that gold may offer”. (We still like gold, but they’re entitled to their view.)
The good news is that one asset class does stand out – cheap stocks. Even though markets massively derated (ie, the amount that investors were willing to pay for a given level of earnings collapsed) during the period, US equities still just about beat inflation between 1967 and 1980, while value stocks did far better. And of them all, commodity stocks did best. “We suspect they did much better than the underlying commodities as a store of value because they were cheap – something that today may well be true again.” For exposure to oil and gas, consider the iShares Oil and Gas Exploration and Production ETF (LSE: SPOG), while for exposure to mining stocks try BlackRock World Mining Trust (LSE: BRWM).
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
John Stepek is a senior reporter at Bloomberg News and a former editor of MoneyWeek magazine. He graduated from Strathclyde University with a degree in psychology in 1996 and has always been fascinated by the gap between the way the market works in theory and the way it works in practice, and by how our deep-rooted instincts work against our best interests as investors.
He started out in journalism by writing articles about the specific business challenges facing family firms. In 2003, he took a job on the finance desk of Teletext, where he spent two years covering the markets and breaking financial news.
His work has been published in Families in Business, Shares magazine, Spear's Magazine, The Sunday Times, and The Spectator among others. He has also appeared as an expert commentator on BBC Radio 4's Today programme, BBC Radio Scotland, Newsnight, Daily Politics and Bloomberg. His first book, on contrarian investing, The Sceptical Investor, was released in March 2019. You can follow John on Twitter at @john_stepek.
-
Lloyds axes foreign currency fees for Club Lloyds customers
Club Lloyds customers will be able to withdraw their money abroad without incurring any extra fees
By Daniel Hilton
-
How to invest during stagflation
Trump’s tariffs look poised to push the global economy into a period of stagflation. We look at how to ensure your investments can survive a global slowdown.
By Dan McEvoy
-
Falling revenues and mounting debt spell trouble for Jumia Technologies
Struggling African e-commerce platform Jumia Technologies looks headed for the exit, says Dr Matthew Partridge.
By Dr Matthew Partridge
-
Next reports £1 billion in annual profits for the first time – what's next for the retailer?
Clothing retailer Next has become only the fourth member of its sector to surpass £1 billion in annual profits. What does this mean for the company's future?
By Dr Matthew Partridge
-
Best of British bargains: cash in on undervalued companies in the UK stock market
Opinion Michael Field, Chief Equity Market Strategist, EMEA, Morningstar, selects three attractive UK stocks where he'd put his money
By Michael Field
-
Building firm Keller presents low debt and ample scope for growth
Geotechnical contractor Keller, which supports vital global infrastructure, boasts rising profits and a cheap valuation
By Dr Mike Tubbs
-
PZ Cussons share price down 75% in last decade – why it's one to watch
Opinion Once-strong consumer-goods business PZ Cussons is out of favour with the market. That spells opportunity for investors, says Jamie Ward
By Jamie Ward
-
Cash in on the biotech sector with specialist trust BioPharma
Opinion BioPharma has an attractive niche in lending to asset-rich biotechnology companies
By Rupert Hargreaves
-
India's stock market decline wipes out $1.3 trillion in market value – can investors stay optimistic?
More than $1 trillion has been wiped off from India's stock market after investors turn to China. Has the emerging-market darling hit rock bottom?
By Alex Rankine
-
Pensions revolution: how to profit from the trends shaping the UK pension system
The UK pension system is one of the biggest in the world. Big changes are under way, says Rupert Hargreaves
By Rupert Hargreaves